Trial Profile
Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccines-Medigene Immnotherapies (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors MediGene AG
- 08 Feb 2021 Follow-up results ( Cut-off date : September 2020 ) are presented in a MediGene AG media release.
- 08 Feb 2021 According to a MediGene AG media release, data from this study are been presented at the virtual Transplantation & Cellular Therapy (TCT) Meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).
- 07 Dec 2020 Results presented in a MediGene AG media release.